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UDP-GlcNAcHyaluronan, a macromolecular glycosaminoglycan, is normally synthesized by hyaluronan synthases at the plas-
ma membrane using cytosolic UDP-GlcUA and UDP-GlcNAc substrates and extruding the elongating chain into
the extracellular space. The cellular metabolism (synthesis and catabolism) of hyaluronan is dynamic. UDP-
GlcNAc is also the substrate for O-GlcNAc transferase, which is central to the control of many cytosolic pathways.
This Perspective outlines recent data for regulation of hyaluronan synthesis and catabolism that support a model
that hyaluronan metabolism can be a rheostat for controlling an acceptable normal range of cytosolic UDP-
GlcNAc concentrations in order to maintain normal cell functions.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The review article in this issue by Vigetti et al. (2014) provides an in-
sightful description of the mechanisms for regulating the stability and
activity of hyaluronan synthase 2 (HAS2), the HAS that is required for
development in vertebrates (McDonald and Hascall, 2002). Cytosolic
UDP-GlcNAc is one of the substrates for hyaluronan synthesis and is
also the substrate for the cytosolic enzyme, O-GlcNAc transferase
(OGT). OGT transfers GlcNAc from UDP-GlcNAc (O-GlcNAcylation) to
serines/threonines inmany intracellular proteins, which is often essential
for regulating their functions. For example, O-GlcNAc is often the alter-
nate structure for sites of phosphorylation on kinases. The activity of
OGT depends on cytosolic UDP-GlcNAc levels. For example, hyperglyce-
mic glucose stress, with consequent increases in UDP-GlcNAc concentra-
tion, leads to aberrant O-GlcNAcylation onmanymore cytosolic proteins,
which can compromise cellular functions (Ma and Hart, 2013). The fol-
lowing Perspective outlines how regulation of HAS2 activity could be an
important regulator for maintaining cytosolic UDP-GlcNAc concentra-
tions within an acceptable level for normal cell function.
2. Hyaluronan biosynthesis
Hyaluronan is a glycosaminoglycan composed of a disaccharide,
(glucuronate-β1,3-N-acetylglucosamine-β1,4-), that can be repeatedl Engineering, ND20, Cleveland
5 5676; fax: +1 216 444 9198.
ights reserved.more than 10,000 times to form a macromolecule N10 MDa in size.
Unlike the other glycosaminoglycans (chondroitin sulfate, heparin/
heparan sulfate, keratan sulfate), biosynthesis of hyaluronan does
not require a core protein and is not synthesized in the Golgi. Instead,
it is normally produced at the plasma membrane by one or more of
the 3 hyaluronan synthases (HAS1, 2, 3) in the mammalian genomes
(Weigel et al., 1997; Tammi et al., 2011).
HASes are synthesized in the endoplasmic reticulum (ER) and car-
ried by transport vesicles, likely through the Golgi, to the plasmamem-
brane in an inactive form. Once embedded in the plasma membrane
they can be activated, most likely through a phosphokinase C (PKC)
phosphorylation pathway (Fig. 1A) (Wang andHascall, 2004). The cyto-
solic domains of HASes then utilize cytosolic substrates (UDP-GlcUA
and UDP-GlcNAc) and add them alternately onto the reducing end of
the chain at the expense of removing the anchoring UDP, and the elon-
gating chain is extruded through the plasma membrane into the extra-
cellular space. During transport to the plasma membrane, the cytosolic
domain is exposed to the cytosol. Therefore, it is important not to acti-
vate HASes before they are properly embedded in the plasma
membrane.
Further, regulation of hyaluronan synthesis is relatively simple as it
depends only on single enzymes. It is also relatively energy efﬁcient as
synthesis of one of the substrates, UDP-glucuronic acid (UDP-GlcUA),
recovers the equivalent of two ATPs, 5 from double oxidation of
NADPH, and minus 3 from the oxidation of UDP-glucose. It is also
quite likely that the rate of hyaluronan synthesis depends on the cyto-
solic concentrations of the UDP-sugar substrates (Jokela et al., 2008;
Rilla et al., 2013).
Fig. 1.Models for regulation of HAS2 synthesis and its relation with UDP-GlcNAc concentration and OGT activity.
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Hyaluronan synthase 2 is expressed by most, if not all, cells and is
essential for life. While the HAS1 and 3 null mice are developmentally
normal, the HAS2 null mouse dies at an early embryonic stage when
the heart is formed. Normal heart development requires endothelial
cells to undergo epithelial–mesenchymal transition (EMT), which
occurs when HAS2 is upregulated. Organ cultures of the wild type
heart tube endothelial cells undergo EMT at the initiation of hyaluronan
synthesis by HAS2. In contrast, organ cultures of the HAS2 null heart
endothelium do not undergo any EMT, but do so if hyaluronan is
added to the culture medium (Camenisch et al., 2002; McDonald and
Hascall, 2002).
HAS2 is dynamically regulated by cytosolic pathways that are
involved in regulation of O-GlcNAcylation. The stability of cytosolic
HAS2 is signiﬁcantly increased when serine 221 is O-GlcNAcylated(t1/2 of ~5 h). In the absence of O-GlcNAc on this serine, HAS2 is rapidly
degraded in proteasomes (t1/2 of ~15 min) (Fig. 1B) (Vigetti et al.,
2012). It is possible that O-GlcNAcylation of this serine is a key for reg-
ulating whether or not HAS2 remains inactivated, which would allow
the enzyme to migrate to the surface after its synthesis in the ER.
Further, it would allow HAS2 to be internalized in an inactive form
into cytosolic vesicles for storage or for eventual lysosomal or
proteasomal degradation as outlined in Fig. 1B. It is also possible that
removal of the GlcNAc and phosphorylation of this site or of another
serine residue is critical for its normal activation in the plasma mem-
brane. In any event, it is necessary tomaintain HASes in non-active con-
ﬁgurations when they are in any membrane exposed to cytosol except
the plasma membrane, as shown by the pathological autophagic
response of dividing hyperglycemic cells discussed below.
During energy stress, the ratio of AMP/ATP increases with conse-
quent activation of AMP kinase. AMP kinase phosphorylates threonine
Fig. 2.Model for catabolism of pericellular hyaluronan glycocalyx matrices.
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(Fig. 1C) (Vigetti et al., 2011). This is a rapid way to help restore ATP
levels back to normal, which would be needed to synthesize the UDP-
GlcNAc substrate.
4. Regulation of hyaluronan synthesis by HAS2
These results indicate several ways for post-transcriptional regula-
tion of hyaluronan synthesis by HAS2. 1) The concentrations of the
UDP-sugar substrates in the cytosol can vary greatly depending on car-
bohydrate metabolism, which could increase or decrease hyaluronan
synthesis accordingly. 2) The number of active HAS2 enzymes in the
plasma membrane could effectively be altered by vesicular transport
to and from the plasmamembrane. 3) The active enzyme can be rapidly
inactivated by AMP kinase under metabolic stress. Central to these
mechanisms are the cytosolic concentrations of the UDP-sugar sub-
strates, critically UDP-GlcNAc, because it is also the substrate for OGT.
In normal conditions, the concentration of UDP-GlcNAc can vary
from metabolism of carbohydrates. When UDP-GlcNAc is increased,
hyaluronan synthesis is rapidly increased, which can effectively reduce
the UDP-GlcNAc pool size to an acceptable cytosolic concentration.
Further, when hyaluronan synthesis is signiﬁcantly increased byoverexpression of HAS, UDP-GlcNAc pools decrease signiﬁcantly (Rilla
et al., 2013). It is also possible that transfer of HAS to and from the plas-
ma membrane can modulate hyaluronan synthesis. During ATP energy
stress, synthesis of the UDP-sugar substrates can be inhibited, and the
rapid inactivation of active HAS2 can help tomaintain effective cytosolic
UDP-GlcNAc concentrations. In these circumstances, hyaluronan syn-
thesis by HAS2 could function as a rheostat for effective maintenance
of UDP-GlcNAc within an acceptable cytosolic concentration.
An interesting feedback inhibition of HAS2 gene expression comes
from the size of the cellularUDP-GlcNAc pool. Increasing and decreasing
cellular UDP-GlcNAc concentration reduces and increases, respectively,
HAS2 mRNA levels in keratinocytes by O-GlcNAcylation of HAS2 gene
regulating transcription factors (Jokela et al., 2011). This can dampen
changes in hyaluronan synthesis from excessive ﬂuctuations in UDP-
GlcNAc levels. However, the feedback appears to fade, at least in smooth
muscle cells subjected to chronic hyperglycemia (Sainio et al., 2010).
5. Hyaluronan catabolism (Fig. 2) (reviewed by Stern, 2004)
Because the hyaluronan being synthesized is extruded into the
extracellular space, an efﬁcient catabolic process would be needed to
remove it if its synthesis is continuously dynamic. This could be by a
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hyaluronan, which ﬂows into lymphatics that can recover most of it
before it enters circulation. Once in circulation, hyaluronan is very effec-
tively removed by hepatic endothelial cells. This efﬁcient process
recovers the sugars by internalization and transport to lysosomes
(Pandey et al., 2008). Most cells do not have this option, but do have a
metabolically active pericellular matrix (glycocalyx). For example,
keratinocytes catabolize hyaluronan by a mechanism that involves the
CD44 hyaluronan receptor (Tammi et al., 2001) and a hyaluronidase,
most likely GPI-anchored hyaluronidase 2 (Andre et al., 2011). The pres-
ence of a protease, such as ADAMTS5 (aggrecanase) is likely also
involved in order to remove associated proteoglycans (aggrecan and
versican) (Hattori et al., 2011). CD44 rapidly transports (t1/2 of ~15
min) the fragmented hyaluronan (20–30 kDa) with any remaining
bound proteins into an endosomal compartment distinct from coated
pits and pinocytotic uptake pathways. The fragments are then
transported to lysosomes for complete degradation (t1/2 of ~3 h)
(Tammi et al., 2001). Therefore, distinct sites for biosynthesis and catab-
olism of hyaluronan on the surface of cells could effectively cooperate in
controlling its dynamic metabolism.
6. Pathological activation of HAS in hyperglycemic dividing cells
(Wang et al., 2011)
Glucose stress from hyperglycemia (≳2.5 × normal glucose levels)
cannot be tolerated by dividing cells. To cope with the increases in cyto-
solic glucose and UDP-sugars, the cells activate a PKC pathway that acti-
vates HAS enzymes in intracellular membrane compartments (Fig. 1D).
Synthesis and deposition of hyaluronan in the endoplasmic reticulum
initiates an ER stress mechanism that induces an autophagy that
upregulates cyclin D3 synthesis, which is then involved in extrusion of
hyaluronan into an extracellular monocyte-adhesive matrix. Mesangial
cells that undergo this process are no longer able to sustain glomerular
function in diabetic rats. The presence of 4-methylumbelliferyl-xyloside
(4MU-xyl), an unnatural substrate for extension of glycosaminoglycan
chains in lieu of core proteins, prevents the indirect intracellular activa-
tion of HASes and the autophagy, which allows the cells to complete nor-
mal cell division. Xylosides enter the cell and the Golgi where they
stimulate synthesis of chondroitin sulfate chains that are secreted into
the medium (Fig. 1E). Mesangial cells increase chondroitin sulfate syn-
thesis ~8 fold in the presence of 4MU-xyl (Nigro et al., 2009). The UDP-
sugar substrates for synthesis of chondroitin sulfate are synthesized in
the cytosol and transported into the Golgi by speciﬁc transporters that
internalize one UDP-sugar while removing one UMP downstream prod-
uct. Increasing chondroitin sulfate synthesis ~8-fold requires antiporters
to remove 8 times more UDP-sugar substrates (UDP-GalNAc and UDP-
GlcUA) from the cytosol. This can effectively diminish cytosolic UDP-
GlcNAc (a precursor for UDP-GalNAc) and UDP-GlcUA, the substrates
for hyaluronan synthesis. Dividing mesangial cells in hyperglycemia in
thepresence of 4MU-xyl donot activate theHAS enzymes in intracellular
compartments, which allows the cells to complete cell division without
the pathological autophagy response. This result provides direct evi-
dence that the control of the cytosolic concentration of UDP-GlcNAc,
and possibly of UDP-GlcUA, is critical for maintaining normal cellular
function during cell division.
In sum, these recent ﬁndings demonstrating the inter-relationships
between UDP-GlcNAc, hyaluronan synthesis and protein O-GlcNAc
modiﬁcations reveal an interesting direct connection of glucose metab-
olism with HAS2 gene expression and regulation of its activity that canmodify the pericellular matrix. Further, changes of hyaluronanmetabo-
lism in these cellular matrices can have extensive and deleterious con-
sequences in major diseases, including inﬂammation, obesity, diabetes
and cancer, which are often linked to disturbed glucose metabolism.Acknowledgments
Original research in the authors' laboratories is supported in part by
P01HL107147 to V.C.H. and by P01HL107153 to G.W.H.References
Andre, B., Duterme, C., Van Moer, K., Mertens-Strijthagen, J., Jadot, M., Flamion, B., 2011.
Hyal2 is a glycosylphosphatidylinositol-anchored, lipid raft-associated hyaluronidase.
Biochem. Biophys. Res. Commun. 411, 175–179.
Camenisch, T.D., Schroeder, J.A., Bradley, J., Klewer, S.E., McDonald, J.A., 2002. Heart-valve
mesenchyme formation is dependent on hyaluronan-augmented activation of
ErbB2–ErbB3 receptors. Nat. Med. 8, 850–855.
Hattori, N., Carrino, D.A., Lauer, M.E., Vasanji, A., Wylie, J.D., Nelson, C.M., Apte, S.S., 2011.
Pericellular versican regulates the ﬁbroblast-myoﬁbroblast transition: a role for
ADAMTS5 protease-mediated proteolysis. J. Biol. Chem. 286, 34298–34310.
Jokela, T.A., Jauhiainen, M., Auriola, S., Kauhanen, M., Tiihonen, R., Tammi, M.I., Tammi,
R.H., 2008. Mannose inhibits hyaluronan synthesis by down-regulation of the cellular
pool of UDP-N-acetylhexosamines. J. Biol. Chem. 283, 7666–7673.
Jokela, T.A., Makkonen, K.M., Oikari, S., Kärnä, R., Koli, E., Hart, G.W., Tammi, R.H., Carlberg,
C., Tammi, M.I., 2011. Cellular content of UDP-N-acetylhexosamines controls
hyaluronan synthase 2 expression and correlates with O-GlcNAc modiﬁcation of
transcription factors YY1 and SP1. J. Biol. Chem. 286, 33632–33640.
Ma, J., Hart, G.W., 2013. Protein O-GlcNAcylation in diabetes and diabetic complications.
Expert Rev. Proteomics 10, 365–380.
McDonald, J., Hascall, V.C., 2002. Hyaluronan minireview series. J. Biol. Chem. 277,
4575–4579.
Nigro, J., Wang, A., Mukhopadhyay, D., Lauer, M., Midura, R., Sackstein, R., Hascall, V.,
2009. Regulation of heparan sulfate and chondroitin sulfate. Glycosaminoglycan
biosynthesis by 4-ﬂuoro-glucosamine in murine airway smooth muscle cells. J. Biol.
Chem. 284, 16832–16839.
Pandey, M.S., Harris, E.N., Weigel, J.A., Weigel, P.H., 2008. The cytoplasmic domain of the
hyaluronan receptor for endocytosis (HARE) contains multiple endocytic motifs
targeting coated pit-mediated internalization. J. Biol. Chem. 283, 21453–21461.
Rilla, K., Oikari, S., Jokela, T.A., Hyttinen, J.M., Kärnä, R., Tammi, R.H., Tammi, M.I., 2013.
Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration
than HAS2 and HAS3. J. Biol. Chem. 288, 5973–5983.
Sainio, A., Jokela, T., Tammi, M.I., Järveläinen, H., 2010. Hyperglycemic conditions
modulate connective tissue reorganization by human vascular smooth muscle cells
through stimulation of hyaluronan synthesis. Glycobiology 20, 1117–1126.
Stern, R., 2004. Hyaluronan catabolism: a new metabolic pathway. Eur. J. Cell Biol. 83,
317–325.
Tammi, R., Rilla, K., Pienimäki, J.-P., MacCallum, D.K., Hogg, M., Luukkonen, M., Hascall,
V.C., Tammi, M., 2001. Hyaluronan enters keratinocytes by a novel endocytic route
for catabolism. J. Biol. Chem. 276, 35111–35122.
Tammi, R.H., Passi, A.G., Rilla, K., Karousou, E., Vigetti, D., Makkonen, K., Tammi, M.I., 2011.
Transcriptional and posttranslational regulation of HA synthesis. FEBS J. 278,
1419–1428.
Vigetti, D., Clerici, M., Deleonibus, S., Karousou, E., Viola, M., Moretto, P., Heldin, P., Hascall,
V.C., De Luca, G., Passi, A., 2011. Hyaluronan synthesis is inhibited by adenosine
monophosphate-activated protein kinase through the regulation of HAS2 activity in
human aortic smooth muscle cells. J. Biol. Chem. 286, 7917–7924.
Vigetti, D., Deleonibus, S., Moretto, P., Karousou, E., Viola, M., Bartolini, B., Hascall, V.C.,
Tammi, M., De Luca, G., Passi, A., 2012. Role of UDP-N-acetylglucosamine and O-
GlcNAcylation of hyaluronan synthase 2 in the control of chondroitin sulfate and
hyaluronan synthesis. J. Biol. Chem. 287, 35544–35555.
Vigetti, D., Viola, M., Karousou, E., De Luca, G., Passi, A., 2014. Metabolic control of
hyaluronan synthases. Matrix Biol.. http://dx.doi.org/10.1016/j.matbio.2013.10.002
(Oct 14).
Wang, A., Hascall, V.C., 2004. Hyaluronan structures synthesized by rat mesangial cells in
response to hyperglycemia induce monocyte adhesion. J. Biol. Chem. 279,
10279–10285.
Wang, A., de la Motte, C., Lauer, M., Hascall, V., 2011. Hyaluronan matrices in
pathobiological processes. FEBS J. 278, 1412–1418.
Weigel, P.H., Hascall, V.C., Tammi, M., 1997. Hyaluronan synthases. J. Biol. Chem. 272,
13997–14000.
